Edition:
United States

Shanghai Pharmaceuticals Holding Co Ltd (601607.SS)

601607.SS on Shanghai Stock Exchange

25.20CNY
26 May 2017
Change (% chg)

¥-0.28 (-1.10%)
Prev Close
¥25.48
Open
¥25.48
Day's High
¥25.61
Day's Low
¥24.94
Volume
8,152,018
Avg. Vol
11,487,142
52-wk High
¥25.80
52-wk Low
¥17.20

Latest Key Developments (Source: Significant Developments)

Shanghai Pharmaceuticals clarifies on reports about co's possible bid for Stada Arzneimittel AG
Tuesday, 16 May 2017 08:44pm EDT 

May 17 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd <601607.SS>:Recently discussed about possibilities of project Stada with a couple of financial investors.Bidding price of 70 euro per share that media mentioned is inconsistent with reality.Refers to reports that co is considering to team up on a bid for German pharmaceutical company, Stada Arzneimittel AG.  Full Article

Advent, Shanghai Pharma said to consider rival bid of about 70 euros a share for Stada - Bloomberg, citing sources
Monday, 15 May 2017 01:40pm EDT 

May 15 (Reuters) - :Advent, Shanghai Pharma said to consider rival bid of about 70 euros a share for Stada - Bloomberg, citing sources.  Full Article

Shanghai Pharmaceuticals posts qtrly net profit of RMB 999.4 mln
Thursday, 27 Apr 2017 06:15am EDT 

April 27 (Reuters) - Shanghai Pharmaceuticals Holding Co Ltd <601607.SS>:Qtrly net profit attributable RMB 999.4 million versus RMB 889.4 million.Qtrly revenue RMB 33.13 billion versus RMB 29.28 billion.  Full Article

Shanghai Pharmaceuticals Holding receives GMP certificate
Wednesday, 22 Mar 2017 10:23pm EDT 

Shanghai Pharmaceuticals Holding Co Ltd <601607.SS> : Says its unit received goods manufacture practice (GMP) certificate from Jiangsu Food and Drug Administration .Says certificate issued to perindopril tert-butylamine manufactured by the company and the valid period is until March 19, 2022.  Full Article

Shanghai Pharmaceuticals to apply to issue debentures worth up to 7 bln yuan
Wednesday, 22 Mar 2017 05:34am EDT 

Shanghai Pharmaceuticals Holding Co Ltd <601607.SS> : Says it will apply to issue debenture worth up to 7 billion yuan .Says proceeds will be used for loan repayment and supplement of working capital.  Full Article

Shanghai Pharmaceuticals to pay FY 2016 annual div as 3.60 yuan/10 shares
Wednesday, 22 Mar 2017 05:23am EDT 

Shanghai Pharmaceuticals Holding Co Ltd <601607.SS> :Says it will pay annual cash dividend as 3.60 yuan(pre-tax)/10 shares to shareholders for FY 2016.  Full Article

Shanghai Pharmaceuticals' 2016 net profit up 11.1 pct
Tuesday, 21 Mar 2017 07:30am EDT 

Shanghai Pharmaceuticals Holding Co Ltd <601607.SS><2607.HK> :Says 2016 net profit up 11.1 percent y/y at 3.2 billion yuan ($464.71 million).  Full Article

Shanghai Pharmaceuticals Holding unit receives GMP certificate
Monday, 20 Feb 2017 01:53am EST 

Shanghai Pharmaceuticals Holding Co Ltd <601607.SS> : Says co's controlling bio-pharmaceuticals unit receives GMP certificate from Shanghai Food and Drug Administration .Certificate is issued to plants of APIs (paclitaxel and docetaxel) in the unit and the valid period is until Jan. 21, 2022.  Full Article

Shanghai Pharmaceuticals updates on progress of participation in privatization of Vitaco
Wednesday, 30 Nov 2016 06:24am EST 

Shanghai Pharmaceuticals Holding Co Ltd <601607.SS> : On 30 November 2016, Vitaco has received approval of Vitaco's shareholders . Refers to announcements in relation to participation of SIIC Medical Science And Technology (Group) Limited in privatization of Vitaco Holdings .Transaction is still subject to approval of Federal Court of Australia.  Full Article

Shanghai Pharmaceuticals clarifies on reports of insider trading investigation
Friday, 4 Nov 2016 09:35am EDT 

Shanghai Pharmaceuticals Holding Co Ltd <601607.SS> : Noted certain media reports have recently stated that Australian securities and investments commission was conducting an investigation . Investigation on senior management of Shanghai Pharma involved in insider trading behavior as to transaction . Jijun referred is management personnel of three-level unit, who is not director, supervisor or senior management of Shanghai Pharma . It has confirmed that none of director, supervisor or senior management involving in transaction involved in investigation . Expected that results of investigation on Ji would not have material impact on company or transaction . Refers to announcements in relation to participating privatization of Vitaco Holdings and update on progress .Transaction obtained approval from foreign investment review board of Australia and New Zealand overseas investment office.  Full Article

More From Around the Web

Photo

Rival investor group not making counter bid for Stada: sources

FRANKFURT Private equity firms Advent and Permira are not planning to tie up with Shanghai Pharmaceuticals to make a counter bid for German generics drugmaker Stada Arzneimittel , four people familiar with the matter told Reuters on Wednesday.